Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17036710 | 0.94 | HCAR2 (0.46) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL17023245 | 0.93 | HCAR2 (0.55) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18405663 | 0.93 | HCAR2 (0.48) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18395418 | 0.93 | HCAR2 (0.48) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL17023244 | 0.93 | HCAR2 (0.55) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18406944 | 0.89 | ATM (0.52) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18405667 | 0.88 | HCAR2 (0.44) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL18395083 | 0.88 | HCAR2 (0.44) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL8685898 | 0.85 | TSHR (0.48) | ATMMAPTALDH1A1MEN1HTT | |
| SCHEMBL18405757 | 0.84 | ATM (0.47) | ATMHCAR2MAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110793-B1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2019-08-21 | — | — | EP | disclosed |
| US-10301256-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-05-28 | — | — | US | disclosed |
| US-20170129851-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-05-11 | — | — | US | disclosed |
| US-9604922-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-03-28 | — | — | US | disclosed |
| US-20170022153-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022153-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-26 | — | — | US | disclosed |
| EP-3110793-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | Alkermes Pharma Ireland Limited (IE) | 2017-01-04 | — | — | EP | disclosed |
| US-20150239829-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2015-08-27 | — | — | US | disclosed |
| WO-2015127450-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022153-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | ATM 4406/4885HCAR2 290/4885MAPT 8/4885 |
| US-10301256-B2 | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases | SULT2A1, FH, STS | ATM 3573/4885HCAR2 544/4885MAPT 485/4885 |
| US-20170129851-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | SULT2A1, FH, STS | ATM 3573/4885HCAR2 544/4885MAPT 485/4885 |
| US-20150239829-A1 | SULFONAMIDE AND SULFINAMIDE PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | SULT2A1, FH, STS | ATM 3573/4885HCAR2 544/4885MAPT 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.